SALT LAKE CITY, November 19, 2024 /PRNewswire/ — Utah-based Second Heart Assist Inc., announced continued successes in additional clinical studies in South America. Through a series of planned studies, Second Heart Assist has yet again demonstrated significant safety and efficacy in OUS trials for its Whisper™ device, uniquely poised to tackle multiple indications of HF including HR-PCI, ADHF, and CS non-invasively. This device can be deployed in under 2 min and has the potential to be the safest, fastest, and easiest to use device to enter the market with the highest perfusion / lowest hemolysis on the market horizon.
Recent Posts
- Controlled Study Demonstrates Significantly Lower Hemolysis of Second Heart Assist Whisper Device Compared to J&J Impella
- Second Heart Assist’s “Whisper” speaks loudly to market needs
- Second Heart Assist Continues With Compelling Momentum and Data – Impressive Clinical Results
- Second Heart Assist Announces Impressive Successful Trials in Central America with its Whisper™ Device
- Latest Advances in Treatment of CHF with Devices